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ABSTRACT 
Chronic diseases are the major causes of morbidity and mortality across the globe 
in developed and developing countries, and in countries transitioning from former 
socialist status. Chronic diseases – including heart disease, cancer, stroke, diabetes, 
and respiratory diseases – share major risk factors beyond genetics and social 
inequalities including tobacco use, unhealthy diet, physical inactivity, and lack of 
access to preventive care. There are evidence-based interventions that are effective 
in modifying these risks and subsequently preventing disease. Evidence for 
prevention is strongest for measures aimed at reducing tobacco use and increasing 
physical activity, while large gaps remain in our knowledge about how to effectively 
change eating habits and achieve healthy weights in a population. The New Public 
Health addresses interventions delivered at three levels: 1) at the level of society, 
where public policy and governmental interventions can change the environment, 
as well as individual behavior (e.g., regulation of tobacco products and food 
composition, taxation, redesigning the built environment, banning advertising); 2) 
at the level of the community, through the activities of local institutions delivered at 
the population level (e.g., school-based and workplace health promotion, community 
education, training, and public awareness campaigns); and 3) at the level of the 
individual, through the provision of clinical preventive services including screening, 
counselling, chemoprophylaxis, and immunizations (in recognition of the growing 
evidence that infections cause important chronic diseases). We conclude with a 
discussion of comprehensive national and international efforts needed to stem the 
tide of the growing global burden of chronic disease.
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INTRODUCTION
The impact of chronic conditions has been underappreciated by society and 
by health systems in terms of its acute social and economic effects on 
populations. Despite accounting for around 60 percent of all deaths 
worldwide, chronic diseases are surprisingly neglected on the public health 
agendas of most nations and regions, particularly in low and middle-income 
countries (LMICs), where more attention has traditionally been paid to 
infectious diseases.1 Once associated with rich, industrialized nations, 
chronic diseases are now the leading causes of death in the developing 
world, as well.2 The largest increase in overall disease burden, mainly due 
to chronic disease, is concentrated in Central Asia. Existing data on 
mortality, years of life lost (YLL), and Disability Adjusted Life Years 
(DALYs) reveal a 10 percent rise in the global burden of disease due to 
chronic diseases in LMICs from 1990 to 2001.3 
The paradigm of how we view chronic diseases is also shifting. The 
relationship between chronic diseases and non-communicable diseases has 
often been confused as synonymous, or at least closely linked; however, this 
notion is increasingly being exposed as outdated. Today, we know that 
infectious agents such as human papillomavirus (HPV), hepatitis B virus 
(HBV), and Helicobacter pylori can cause cancer of the cervix, liver, and 
stomach, respectively. Moreover, as life expectancies rise in most countries 
due to better and more available healthcare, chronic disease prevalence is 
increasing in populations that perhaps would have had shorter life expectancy 
in the past, presenting new demands for struggling health systems to improve 
the health of the middle-aged and the elderly. Likewise, our knowledge on 
how to combat some diseases such as HIV/AIDS, is gradually transforming 
once fatal infectious diseases into long-term chronic conditions. 
These trends, together with the worldwide increase in hypertension and 
cancer due to population aging and modifi  cations in health behaviors, 
contribute to the sharp rise in the prevalence of chronic diseases. These 
pathologies now cause the greatest share of death and disability in the 
world. In 2005, at least 35 million people of all ages, nationalities, and 
socioeconomic levels died from heart disease, stroke, cancer, diabetes, 
respiratory disease, and other chronic diseases.4 In this paper, we have 122  Public Health Reviews, Vol. 32, No 1
chosen to focus on three major chronic conditions: cardiovascular disease 
(CVD) (heart disease and stroke), cancer, and diabetes. Together, these 
conditions are not only responsible for most chronic disease morbidity, but 
also around 45 percent of total mortality worldwide.1
We describe global trends in chronic disease burden and epidemiology, 
including those factors in play in increasing or decreasing the incidence, 
prevalence, and mortality of these broad disease categories. We also review 
current knowledge of effective preventive strategies, encompassed under 
the concept of the New Public Health. Traditional public health activities 
were highly successful in limited areas of sanitary and hygienic activities, 
surveillance of infectious diseases and clinical interventions (such as 
vaccinations, and maternal and child health). The New Public Health refers 
to a more holistic, multidisciplinary, and multi-sectoral approach to 
improving population health by tackling risk factors at an individual, 
community, and societal level. 
GLOBAL SPREAD OF CHRONIC DISEASE OVER THE PAST 
TWENTY YEARS
Cardiovascular Disease
Approximately 17 million people die annually of CVD, making it the 
leading cause of death worldwide. However, since 1950, we have made 
considerable progress in reducing this disease burden. Age-adjusted death 
rates from CVD in the United States, as in most industrialized nations, have 
declined 60 percent, representing one of the most important public health 
achievements of the 20th century.5 This progress is due to improved 
prevention, diagnosis, and treatment, in particular reduced tobacco use 
among adults, lower levels of blood pressure and blood cholesterol, and 
widespread use of effective medical treatments.6 Paradoxically, however, 
the burden of disease is still rising. Demographic changes brought on by 
aging and longer life expectancy result in greater numbers of elderly 
people, and consequently more deaths due to CVD, despite the improved 
adjusted mortality rates.7 
CVD constitutes an even bigger threat in LMICs, where 80 percent of 
the global disease burden is found. Variations in death rates are marked: 
they are lower in populations with short life expectancy and begin to rise as 
the middle class expands. Thus, it is no surprise that the prevalence of 
these diseases is rising most quickly in Southeast Asia and the Eastern 
Mediterranean regions.8,9 Chronic Disease in the New Public Health  123
Stroke is an important element of CVD morbidity, disability and 
mortality. However, the burden does not fall evenly throughout all 
populations. Those who have suffered one stroke are particularly vulnerable 
to further episodes. Although incidence is higher for men, strokes affect 
women more seriously.10 Furthermore, relatively disadvantaged racial, 
ethnic, and socioeconomic groups show higher incidence rates. While such 
variations also occur within countries, the excess burden of stroke mortality 
is concentrated in Russia and the Newly Independent States, as well as 
Mongolia, sub-Saharan Africa, China, and India.5 Moreover, even where 
advanced technology and facilities are available, 60 percent of those who 
suffer a stroke die or become dependent. Given these bleak statistics and 
the high cost of treatment and long-term care, preventive strategies, such as 
prevention and control of hypertension, are our most effective tools in 
fi  ghting this disease.11
Indeed, hypertension – a major risk factor for CVD and other pathologies 
– constitutes a heavy social and economic burden because it directly 
contributes to the loss of DALYs for citizens and represents considerable 
healthcare expenditures for society12; untreated hypertension shortens life 
expectancy by approximately fi  ve years.13 Despite therapeutic advances, 
prevalence is increasing worldwide,14 as is the number of people with 
uncontrolled high blood pressure.15 In 2000, over a quarter of the world’s 
adult population had hypertension, and the proportion is expected to 
increase to 29 percent by 2025.16 While population aging is a signifi  cant 
factor in this rise, it is an incomplete explanation of why mortality and 
disease burden are increasing. Rodgers and colleagues have noted that up 
to 43 percent of the disease burden due to hypertension occurs in adults 
under 60 and is evenly distributed among men and women.17
Cancer
Until recently, any cancer diagnosis evoked the specter of a long, painful 
death; fortunately, research and medical sciences have made great strides 
in discovering the causes and fi  nding effective treatments. At least one-
third of cancer is now preventable and another third can be detected early 
and treated effectively.18,19 Yet achieving the full potential for prevention 
and treatment of cancer poses signifi  cant challenges, particularly as the 
world population ages in the coming decades. Assuming an annual increase 
in cancer incidence and mortality of 1 percent, by 2030 there could be up 
to 26.8 million new cases of cancer and 17.1 million cancer deaths every 
year, as well as 80 million people living with cancer within 5 years of 
diagnosis.20 124  Public Health Reviews, Vol. 32, No 1
In 2007, there were over 12 million new cancer cases, 7.6 million cancer 
deaths, and over 24 million cancer survivors globally. The most common 
cancers diagnosed globally were lung cancer (1.5 million), breast cancer 
(1.3 million), and colorectal cancer (1.2 million). Lung cancer (1.45 million 
deaths) ranked fi  rst in the mortality scale, followed by stomach cancer 
(800,000 deaths), and liver cancer (680,000 deaths). Among men, the most 
common causes of cancer mortality are lung, stomach, liver, colorectal, 
esophagus and prostate; among women they are breast, lung, stomach, 
colorectal and cervical.21,22
Incidence, prevalence, and survival rates for specifi  c cancers reveal 
much about health equity within and between countries. This is less clear 
for poor-prognosis cancers, such as pancreatic cancer, where relatively 
little is known about their causes, and the mortality rates for those diagnosed 
approaches 100 percent worldwide. Those cancers that are highly 
susceptible to preventive measures, screening, and treatment tell a different 
story. Easily treatable if women undergo regular Pap screening,23 cervical 
cancer is a clear case where secondary prevention and treatment can avert 
hundreds of thousands of deaths of relatively young women globally. 
Moreover, new knowledge on the fundamental role of the HPV as a direct 
cause of cervical cancer has led to development of effective vaccines 
against this infection, which has opened the possibiltity of controlling and 
potentially eliminating this disease – at least in areas where girls and 
women have access to imm  unizations.24,25
Diabetes Mellitus 
Diabetes mellitus is a major risk factor for heart disease, stroke, 
hypertension, dyslipidemia, Metabolic Syndrome, and end stage r    enal 
disease.26 CVD mortality among persons with diabetes is estimated at about 
75-80 percent,27 with markedly worse results for men.28 Currently affecting 
about 285 million people worldwide, the prevalence of diabetes is projected 
to increase over 50 percent in the next 20 years, reaching 438   million 
people, or nearly 8 percent of the adult population.29 The most at-risk 
individuals are those suffering from dysglycaemia, or the disturbance of 
blood-sugar regulation.30 
The main risks driving prevalence of diabetes upwards are related to 
poor diet, lack of physical activity, and obesity. The westernization of 
lifestyles and increased urbanization originating in industrialized nations 
has spread to LMICs, as well. Thus, as with CVD and cancer, most of 
the growing burden of diabetes will be borne by the developing world.31,32Chronic Disease in the New Public Health  125
CHRONIC DISEASE EPIDEMIOLOGY: SHARED RISK FACTORS 
Evidence shows that morbidity and mortality from chronic diseases can be 
greatly decreased by reducing the prevalence of the major behavioral risk 
factors for these conditions. Tobacco use, unhealthy diet, and lack of 
sustained physical activity are associated with many chronic conditions, as 
are specifi  c preventable infections that lead to chronic disease. Because of 
the shared impact of these risk factors, a concerted effort to modify health 
behaviors inevitably has positive repercussions on the disease burden for 
CVD (heart disease and stroke), cancer, diabetes, respiratory diseases, and 
many other conditions. Estimations carried out by Ezzati and colleagues 
affi  rm that a concerted effort to target key risk factors for chronic diseases 
could have important repercussions on healthy life expectancy.33 This 
strategy of changing health behaviors, together with increasing awareness 
of chronic conditions, and promoting the timely use of disease-screening 
practices, should be central to any effective and comprehensive public 
health strategy to prevent chronic disease.34 
Tobacco Use 
Scientifi  c evidence of harm caused by smoking cigarettes reached a critical 
turning point in the mid-1960s.35 At present, nearly 40 causes of death are 
known to be associated with tobacco use,36 making it the most avoidable 
risk factor for premature death in the world. Tobacco has surpassed 
hypertension as the number one risk factor for loss of DALYs in developed 
regions,37 where the burden is evenly distributed among men and women. 
Globally, tobacco-related illnesses cause almost 5 million deaths a year, 
most of them among men in developing countries.38 Recent fi  gures on 
tobacco prevalence indicate that the future disease burden linked to tobacco 
use will continue to rise (Figure 1). 
Environmental tobacco or second-hand smoke, which is a Group 1 
carcinogen, leads the list of avoidable risk factors for cancer, causing 
between 16 percent (in developing countries) and 30 percent (in industrialized 
countries) of cancers worldwide.39 Nearly all lung cancers (about 87-91 
percent in men and 57-86 percent in women)40 are attributable to tobacco 
use, along with most cancers of the esophagus, larynx, and oral cavity. 
Tobacco is also a signifi  cant risk factor for cancers of the bladder, pancreas, 
kidney, stomach, cervix, and nose, as well as myeloid leukaemia.25 
Accumulated evidence has also established a direct causal link between 
tobacco use and CVD.41 Smokers are twice as likely as non-smokers to die 
from coronary heart disease,42 and they are at serious risk for sudden cardiac 126  Public Health Reviews, Vol. 32, No 1
death due to acute coronary thrombosis and stroke.43,44 Moreover, over 
50,000 deaths from ischemic heart disease are associated with secondhand 
smoke annually,45 making exposure to tobacco smoke a concern for the 
entire population, not just those who use tobacco products.
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Fig. 1. Age-standardized estimates for smoking among adults, weighted by sex, 
2006.
Source: WHO. WHO report on the global tobacco epidemic, 2009: Implementing smoke-free 
environments. Geneva: World Health Organization; 2009. 
Tobacco use also increases the risk of acquiring or worsening diabetes.46 
It is associated with poorer metabolic control in persons with diabetes,47 as 
well as an increased risk for development of micro- and macrovascular 
complications and mortality.48,49
Diet, Physical Activity, and Obesity
These three risk factors are separate but closely intertwined and should 
therefore be considered both alone and in concert. Taken as a whole, the 
convergence of a poor diet, an inactive lifestyle, and obesity are a lethal 
combination to health, increasing the risk of developing a long list of 
chronic conditions, including CVD, diabetes mellitus, and cancer, as well 
as metabolic syndrome, gallbladder disease, osteoarthritis, and others. 
Obesity has reached epidemic proportions in industrialized nations and is 
rapidly rising in developing countries,50 affecting women more than 
men.17 Chronic Disease in the New Public Health  127
Global dietary patterns are increasingly characterized by greater intake 
of high caloric sugar sweeteners, salt, animal fats, and edible oils. 
Meanwhile, energy expenditure is being reduced at work, at home, and 
during leisure activities, affecting all age groups. The inexorable trends of 
declining food prices, increased access to supermarkets, and large-scale 
urbanization are key underlying factors that drive these trends.51 Despite 
the acute urgency of the problem, we still have much to learn about how 
these risk factors contribute to chronic diseases, and how to reverse the 
trend.52
Considering Diet Patterns over Diet Content
Gradually, nutritional epidemiology has moved from analyzing specifi  c 
food items or micronutrients and their benefi  ts or harms towards a more 
holistic view that identifi  es diet patterns and tendencies. Of these, the 
“Mediterranean diet,” or “prudent diet” is the most commonly cited in a 
positive light. The term refers to dietary patterns found in olive-growing 
areas of the Mediterranean region, where there are common features in the 
consumption of specifi  c foods and nutrients, such as olive oil as the main 
source of fat, whole grain cereals, a variety of fresh vegetables (plant foods) 
and fruits (as the main and usual dessert), frequent consumption of fi  sh, 
moderate but consistent wine consumption with meals, and relatively low 
amounts of red meat. Among the common components identifi  ed in such a 
diet are: a high monounsaturated/saturated fat ratio and omega-3 fatty 
acids; ethanol intake at moderate levels; high intake of fi  ber, vitamins, 
folate, and natural antioxidants; and low intake of animal protein, all 
benefi  cial for human health.53,54 
Physical Activity
Physical activity and cardiorespiratory fi  tness, inversely associated with 
CVD morbidity and mortality, are promising pathways towards reducing 
chronic disease risk and improving overall health. Studies have shown that 
sustained physical activity at moderate to vigorous levels yields multiple 
health benefi  ts at all ages, including a lower risk of incident diabetes and 
hypertension. Moreover, moderate to vigorous exercise training can lower 
blood pressure in hypertensive adults55,56 and act as a protective factor for 
some types of cancer, independently of weight.57 As populations age, the 
importance of routine physical activity (e.g., walking rather than driving) 
will play an increasingly important role in health promotion.58128  Public Health Reviews, Vol. 32, No 1
Obesity
Obesity, usually a direct result of poor diet and physical inactivity, is 
associated with a high risk of morbidity and mortality in the general 
population and is responsible for up to 39 percent of the global burden of 
CVD, causing worsening and rapid progression of diabetes, hypertension, 
dyslipidemia, and other components of the metabolic syndrome.59 Excess 
weight also increases low-density lipoprotein cholesterol, hypertrigly-
ceridemia, and glucose intolerance, and affects cardiac structure through 
direct maladaptive effects.
Obesity is also an important risk factor for several types of cancers. 
In Western Europe, overweight and obesity are the main causes of approxi-
mately 11 percent of colon cancer, 9 percent of breast cancer, 39 percent of 
endometrial cancer, 37 percent of esophageal adenocarcinomas, 25 percent 
of kidney cancer, and 24 percent of gallbladder cancer.25
Obesity and physical inactivity are both independent risk factors for 
type 2 diabetes, but obesity seems to play a more important role. The 
excessive free fatty acid released by adipose tissue leads to a decrease in 
insulin sensitivity of muscle, fat, and liver, which is followed by higher 
glucose levels and insulin resistance. Physical activity may increase insulin 
sensitivity, glucose disposal, and free fatty acid’s oxidative capability. 
However, it has no noticeable effect on glucose regulation, insulin action, 
and other metabolic complications in obese individuals without additional 
weight loss. The positive biological interaction between obesity and 
physical inactivity support this combined pathophysiology.60
Infectious Agents
In addition to behavioral risk factors, infectious agents have also been 
found to increase the risk of developing some cancers.61,62 The most well 
known of these is HPV, present in virtually all cervical cancer biopsies and 
5.2 percent of total cancers.24 Likewise, hepatitis B (HBV) and hepatitis C 
(HCV) (together accounting for 4.9 percent of all cancers) are important 
risk factors for liver cancer and cirrhosis; and Helicobacter pylori (HP) (in 
5.5 percent of all cancers) causes up to 65 percent of stomach cancers, in 
addition to much suffering from chronic peptic ulcers.63 AIDS is also 
strongly associated with many cancers, particularly Kaposi’s sarcoma and 
Non-Hodgkin’s Lymphoma, but also Hodgkin’s disease, myeloma, brain 
cancer, testicular cancer, and others.64 Chronic Disease in the New Public Health  129
INTERVENTIONS FOR CHRONIC DISEASE PREVENTION 
A comprehensive and integrated New Public Health approach to chronic 
disease prevention focuses on the shared risk factors that contribute to 
the global burden of chronic disease morbidity, disability, and premature 
death. The prevention of chronic disease involves adopting effective 
interventions targeted at the major risk factors for chronic disease.65 
Below, we rely on the growing scientifi  c evidence base to identify the most 
effective interventions targeted at the individual, community, and population 
levels.68 
Evidence is strongest for measures aimed at reducing tobacco use and 
increasing physical activity in Western populations, while large gaps 
remain in our knowledge about how to effectively change eating habits and 
achieve healthy weights in a population. Despite valuable studies in lower 
income contexts,66 the validity of many research results has not been 
established outside the industrialized world. In particular, many of the 
interventions that rely on the delivery of primary and preventive healthcare 
services are probably not feasible in many LMICs, where infrastructure is 
limited and funding is severely constrained.
Below we review the fi  ndings of available research, sharing recom-
mendations that are strongly supported by current scientifi  c evidence. It 
should be noted, however, that this fi  eld is extremely dynamic, with new 
research on clinical preventive care, as well as community- and population-
based interventions, emerging constantly. These circumstances – and the 
millions of lives that can be saved through effective public policy and 
public health action – demand that chronic disease prevention remain a top 
research priority. 
Interventions are discussed under the three major strategies that 
effectively reduce chronic disease risk in a population: healthy public 
policy, community-based programs, and clinical preventive services.67 
Healthy Public Policy
The fi  rst, also sometimes referred to as Health in All Policies, alludes to 
public policy and governmental interventions designed to change both the 
environment, as well as individual behavior to promote health and prevent 
chronic disease throughout society. The 1974 Lalonde report reopened the 
concept of a broad link between population health and economic, social, 
lifestyle, and environmental policy, in addition to genetic potential and 
medical care.68 Since then, evidence has mounted to support intersectoral 
approaches across a broad spectrum of government actions as a key to 
effective public health improvement. 130  Public Health Reviews, Vol. 32, No 1
Community-Based Programs
The second are community interventions by local institutions delivered 
at the population level. These may include school-based and workplace 
health promotion, community education, communication, training, public 
awareness campaigns, social support, city redesign, and public health and 
healthcare delivery system reforms.69 
Clinical Preventive Services
Clinical preventive services delivered by health professionals to individuals 
are effective in the prevention and early detection of disease. Again, it is 
likely that LMICs face the greatest challenge in adopting this approach 
without signifi  cant development of their primary care infrastructure and 
resources targeted for this purpose.
The old nomenclature of “primary, secondary, and tertiary” prevention 
has been replaced by a taxonomy that describes the discreet preventive 
services delivered by health workers to patients. The problem with the old 
taxonomy is that services often fell under more than one category. 
Counselling services, for example, regarding tobacco use or healthy diet 
can be primary, secondary, and tertiary prevention. Instead, we have 
adopted the nomenclature used by the U.S. Preventive Services Task Force 
that categorizes preventive care into four types of services: 1) behavioral 
counselling services, 2) screening tests for asymptomatic disease, 3) 
chemoprophylaxis, and 4) immunizations.70 
It should also be pointed out that most of the preventive services 
recommended here have been found to be highly cost-effective, though not 
necessarily cost-saving. By cost-effective, we mean that the cost per 
quality-adjusted life year (QUALY) is relatively low and the reduced 
burden of disease is relatively high. In a recent systematic review of the 
effectiveness and cost-effectiveness of clinical preventive services, the 
following were identifi  ed as being highly cost-effective for preventing 
chronic disease: aspirin chemoprophylaxis, tobacco use screening and brief 
intervention, hypertension screening, as well as colorectal, cervical, and 
breast cancer screening.71 Each of these is discussed in more detail below.
Reducing Tobacco Use and Exposure
Interventions to decrease the use of tobacco and exposure to second-hand 
smoke in a population are effective at all three levels – public policy, 
community-based programs, and individual clinical preventive services. 
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and disease is well established. The WHO Framework Convention on 
Tobacco Control, a set of effective and cost effi  cient measures to reduce 
tobacco consumption and exposure, embodies this approach and provides a 
blueprint for the 167 countries which have ratifi  ed the treaty so far, which 
have chosen to address this risk factor in a comprehensive way.72 
In addition, the evidence-based Clinical Practice Guideline for Treating 
Tobacco Use and Dependence developed by the U.S. Agency for Healthcare 
Research and Quality recommends specifi  c treatments to help tobacco 
users quit based on a comprehensive review of the scientifi  c literature on 
their effi  cacy and effectiveness.73
While all of the interventions detailed below have some impact when 
considered alone, there is a clear added value when they are implemented 
together, indicating that a truly comprehensive response from all levels of 
society is necessary in order to achieve the best results in tobacco use 
prevention and cessation.
PUBLIC POLICY FOR REDUCING TOBACCO USE AND EXPOSURE
Effective public policies that reduce tobacco use are reviewed below and 
include policies to reduce the demand for and restrict the supply of tobacco 
products, as well as to protect the public against harmful exposure to 
second-hand smoke.69,72 A 2003 review of tobacco control efforts around 
the globe found that tobacco use can be reduced cost-effectively in high-, 
middle- and low-income countries.74 Some of the most effective public 
policies designed to reduce consumption of tobacco products are those that 
decrease the demand for tobacco. These include:
Raising excise taxes on tobacco: Excise taxes are effective in reducing 
tobacco use in adolescents and adults, reducing tobacco consumption, and 
increasing tobacco cessation.69,72
Lowering the cost of treatments: Removing all out-of-pocket costs for 
tobacco dependence treatments (including behavioral counselling, nicotine 
replacement therapy, and other smoking cessation medications) is effective 
in increasing their use and subsequent quit rates.69,72 
Non-price policies are widely used regulatory approaches which are 
also effective in reducing demand for tobacco and include: 
Regulating exposure to environmental tobacco smoke: Smoking bans 
and restrictions of tobacco use in indoor workplaces, public transportation, 
public indoor spaces, and other public places are effective in reducing 
exposure to environmental tobacco smoke.69,72132  Public Health Reviews, Vol. 32, No 1
Regulating the contents of tobacco products: Policies that require 
manufacturers and importers of tobacco products to disclose information 
about the toxic contents and harmful emissions of tobacco products to 
governmental authorities and the public are effective in reducing the 
demand for tobacco products.69,72
Regulating packaging and labelling: Policies that require that each 
pack and carton of tobacco products and any outside packaging and 
labelling carry health warnings on the harmful effects of tobacco use and 
toxic emissions of tobacco products are effective in reducing the demand 
for tobacco products.69,72
Banning tobacco advertising, promotion, and sponsorship: A compre-
hensive ban on advertising, promotion, and sponsorship of tobacco products 
reduces their consumption, as does a comprehensive ban on cross-border 
advertising, promotion, and sponsorship.69,72
Public policy is also effective in reducing the supply of tobacco products:
Prohibiting tobacco sales to minors: Prohibiting the sale of tobacco to 
minors combined with active enforcement of retailer sales laws is effective 
in reducing the accessibility of tobacco products to minors, as is prohibiting 
the manufacture and sale of tobacco-related sweets, snacks, toys or any 
other tobacco products targeted to minors.69,72
Regulating physical access to tobacco products: Banning the sale of 
tobacco products in any manner that makes them directly accessible, such 
as on store shelves, and adopting a total ban on vending machine sales, 
reduces access to tobacco products.69,72
Eliminating illicit trade: The elimination of all forms of illicit trade of 
tobacco products is an effective component of tobacco control, reducing 
access to tobacco products.72 
COMMUNITY-BASED PROGRAMS TO REDUCE TOBACCO USE
Education, communication, training, and public awareness to reduce tobacco 
rely on a variety of methods. Mass media campaigns to reduce tobacco use, 
particularly targeted at adolescents, are effective when implemented with 
excise tax increases and community-based education programs.69 Training 
and awareness programs on tobacco control should be targeted to health 
workers, community workers, social workers, media  professionals, 
educators, decision-makers, and administrators. Communication to promote 
tobacco use cessation should also be targeted to institutions such as schools, 
healthcare facilities, workplaces, sporting, and other group environments. Chronic Disease in the New Public Health  133
Communications to public and private agencies and non-governmental 
organizations increase their awareness of and participation in tobacco 
control programs including the development and implementation of 
intersectoral programs and strategies.
Worksite health promotion programs: Worksite cessation interventions 
(e.g., group and individual counselling, nicotine replacement therapy) are 
effective in helping employees quit,75 as are smoke-free regulations. 
Worksite incentive programs and competitions to increase cessation are 
also effective when combined with the above interventions.69
Healthcare delivery system changes to support quitting: Provider 
reminder systems (e.g., chart stickers, expanded vital signs checklists, 
fl  owcharts, electronic reminders) are effective in increasing the rates at 
which providers deliver advice to quit for patients who use tobacco.69,73 In 
addition, providing insurance coverage for or subsidizing the costs of 
tobacco dependence treatments is effective in increasing use of treatments 
and successful quitting.69,73 
CLINICAL PREVENTIVE SERVICES FOR TREATING TOBACCO 
USE AND DEPENDENCE
The healthcare system and both primary care and specialty medical 
professionals have an important role to play in assisting tobacco users to 
quit.73 However, in LMICs, where access to and affordability of preventive 
care is lacking, the public policy and community-based interventions are 
likely to be most effective and feasible.
Clinical Practice Guidelines: Adoption and dissemination of 
comprehensive, evidence-based clinical practice guidelines on treating 
tobacco dependence to medical professionals are effective in promoting 
cessation of tobacco use and providing adequate treatment. Guidelines 
address the diagnosis and treatment of tobacco dependence and provision 
of counselling services and pharmacotherapy to support cessation.73
Pharmaceuticals: Pharmaceuticals for treating tobacco use and 
dependence that are effective and have been approved by the Food and 
Drug Administration in the US include nicotine replacement therapy 
(chewing gum, throat lozenge, inhaler, transdermal patch, and nasal spray), 
bupropion SR, and varenicline. Combination therapies are also effective.73
Screening: Healthcare providers should ask patients about their tobacco 
use at every visit and document their status in the medical record.73 
Health Behavior Programs: Brief tobacco cessation counselling 
interventions offered to all adults, including pregnant women, are effective 134  Public Health Reviews, Vol. 32, No 1
and include screening for tobacco use, three minutes or less of counselling, 
and/or offering pharmacotherapy.73 These programs are effective in 
increasing quit rates when adopted in both clinical and community 
settings.70 In addition, proactive telephone counselling with multiple 
sessions is effective in helping smokers quit and can reach large numbers of 
smokers.69,73,76 
PHYSICAL ACTIVITY
Public Policy to Increase Physical Activity
The positive health effects of changing the built environment through land 
use redesign to promote physical activity are remarkable and constitute a 
fascinating area where disease prevention and urban planning intersect.77 
Effective policies to increase physical activity in a community involve 
changing planning and development of the physical environment to include 
design elements that take into consideration the distance from residential 
areas to stores, workplaces, schools, and recreation areas, the continuity 
and connectivity of sidewalks and streets, aesthetic and safety aspects of 
the physical environment, and policies such as zoning regulations, building 
codes, builders’ practices, and other governmental policies.69 
Selected changes at a neighbourhood level can also bring positive 
results when physical activity is facilitated through changes in roadway 
design standards and environment. Design components include improved 
street lighting, infrastructure projects to increase safety of street crossings, 
use of traffi  c calming approaches (e.g., speed bumps, traffi  c circles), and 
enhancing street landscaping.69 This New Public Health approach to urban 
planning is of crucial importance and could have important repercussions 
in population health, particularly for those who cannot or do not fi  nd 
opportunities to follow an exercise regimen. 
COMMUNITY-BASED PROGRAMS FOR PHYSICAL ACTIVITY
Highly visible, broad-based, multi-component strategies can also work to 
increase physical activity in a community, particularly through education, 
communication, training, and public awareness campaigns.69 The goal of 
all interventions should be to make physical activity easy and desirable, by 
increasing the social component of exercise and providing education on its 
positive health effects. A simple example of an effective way to increase the 
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at elevators, which inform people of the health benefi  ts of stair-climbing. 
Such prompts point out an immediate opportunity to be more active.69
For children and adolescents, school health education and enhanced 
physical education curricula (including more time spent on moderate to 
vigorous exercise) can contribute to improved health awareness and 
physical fi  tness.69 Likewise, classes for children and parents aimed at 
reducing screen time (time in front of the TV or computer) are an effective 
way to improve weight-related outcomes.69
Community coalitions, including businesses and other agencies, can 
contribute by political advocacy, raising population awareness and helping 
to increase access to exercise facilities by creating walking trails, building 
exercise facilities, or facilitating access to existing resources.69 Including a 
social element is also important; interventions that create and maintain 
supportive relationships for behavior change can include setting up a buddy 
system and making contracts with others to complete specifi  ed levels of 
physical activity, or setting up walking groups, sports teams or other groups, 
which provide friendship and support.69
CLINICAL PREVENTIVE SERVICES TO INCREASE PHYSICAL 
ACTIVITY
Adopting and disseminating existing evidence-based clinical practice 
guidelines for increasing physical activity are also effective.78 The following 
evidence-based guidelines recommend levels of physical activity for 
different age groups of the population:
Children and adolescents: 60 minutes (1 hour) or more of physical 
activity per day is recommended, including aerobic activity, muscle 
strengthening, and bone strengthening.
Adults and older adults (65 years and older who are generally fi  t and 
have no limiting health conditions) – 150 minutes (2.5 hours) a week of 
moderate to vigorous activity spread out during the week for at least 10 
minutes at a time, including aerobic activity and muscle strengthening. 
Activities as simple as walking and gardening will provide a level of 
physical activity suffi  cient to achieve health benefi  ts.
Finally, implementing behavior change programs adapted to each 
individual is effective in increasing physical activity and improving 
physical fi  tness among adults and children.69136  Public Health Reviews, Vol. 32, No 1
HEALTHY DIET
Public policy for a healthy diet
Based on the successful use of public policy for tobacco control and 
increasing physical activity, several public policies have been proposed and 
implemented to restrict the supply of or access to unhealthy foods, as well 
as to increase availability and demand for healthy foods. Given the dynamic 
context in which these policies are emerging, there is an urgent need for 
research to evaluate their effectiveness on changes in dietary patterns and 
clinical outcomes.
Examples of policy to restrict access to unhealthy foods and increase 
access to healthy foods include:79
●   Tort liability against the food industry for failing to disclose health 
risks, deceptive practices, and false advertising of health claims79; 
●   Replacement of unhealthy foods in school cafeterias with increased 
choices of fruits, vegetables, and nutritious alternatives80;
●   Disclosure requirements for food labelling, identifying ingredients, and 
posting warnings79;
●   Regulation of food advertising and marketing to children81; 
●   Taxation of high-energy, low-nutrient foods (e.g., sweetened soft drinks)82;
●   Decreasing the salt content of prepared foods through regulation or 
prohibition combined with mass media campaigns to educate 
populations on the benefi  ts of reducing salt intake83,84;
●   Zoning laws that regulate the location of fast food establishments85 and 
expand access to fruits and vegetables (e.g., farmers markets)86; and 
●   Prohibiting the use of specifi  c ingredients in the food supply (e.g., 
trans-fats).79,87
Community-based programs for a healthy diet
While interventions are needed to increase access to healthier foods in 
communities, very little research has evaluated the effectiveness of such 
programs. Programs that have experienced some early success include 
supporting community gardening to grow vegetables and fruits, introducing 
healthier foods and beverages to local stores, and making farmer’s markets 
available to urban communities.86 Fortifying foods with micronutrients
is a longstanding method of increasing population levels of essential 
micronutrients that can be diffi  cult to obtain particularly for people on low 
incomes (iodine in salt; folic acid, iron, vitamin B and B12 in fl  our; and 
vitamin D in milk), and is also an effective and effi  cient way to reduce these 
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Several intervention studies have shown the positive effect that 
components of the “Mediterranean diet” have on chronic disease markers 
such as blood pressure, lipid profi   les, oxidative stress levels, insulin 
resistance, and body fat.89,90 Studies have shown that adherence to the 
Mediterranean diet reduces the risk of CVD, metabolic syndrome, and 
diabetes.91,92 However, further evidence is needed to formulate feasible and 
effective interventions, including ensuring access to these foods and 
increasing long-term compliance, and identifi  cation of the most effective 
methods for implementing programs in diverse communities.93,94
Worksite programs to control overweight and obesity
Worksite programs intended to improve diet and/or increase physical 
activity behaviors are effective in reducing weight among employees. 
Effective interventions include information and educational strategies, 
behavioral and social strategies, as well as policy and environmental 
approaches to increase access to healthful food and provide opportunities 
for physical activity.69
Clinical preventive services for a healthy diet
As with tobacco and physical activity, comprehensive, evidence-based 
guidelines on healthful diets are important in clinical preventive efforts. 
Research fi  nds that exposure to certain foods is associated with either 
decreased or increased risks for specifi  c chronic conditions, providing clear 
support for clinical interventions.95,96 
Evidence on specifi  c food items supports the recommendation for a 
balanced diet (such as the Mediterranean diet) rich in fruits, vegetables, 
legumes, whole grain cereals, nuts, fi   sh (especially oily fi  sh),  and 
unsaturated fats. Valuable components include iodized salt (and other 
micronutrients such as iron and folic acid in fl  our or supplements such as 
vitamin D at recommended levels) and foods that contain lycopene (mostly 
tomatoes and tomato products; also grapefruit, watermelon, guava, and 
apricot), and selenium (found in roots and tubers, most notably potatoes), 
which are protective against prostate cancer in men. 
It is also important to limit consumption of energy-dense, nutrition poor 
foods high in total fat, saturated fat, sugar, and salt (sodium). The intake of 
trans-fatty acids, free sugars, beta-carotene supplements (associated with 
increased risk of lung cancer), and calcium-rich foods (associated with 
increased risk of prostate cancer) should be reduced or elimated.138  Public Health Reviews, Vol. 32, No 1
SCREENING FOR OBESITY
Body mass index (BMI = kg/m2) is a valid method for screening and 
identifying adults who are overweight or obese. High-intensity counselling 
about diet, exercise or both, together with behavioral interventions are 
effective in producing modest, sustained weight loss (typically 3-5 kg for 1 
year or more) in adults who are obese (defi  ned as BMI ≥ 30 kg/m2). Modest 
weight loss is effective in improving intermediate health outcomes, such as 
glucose metabolism, lipid levels, and blood pressure, but does not reduce 
mortality.70
Among adult patients with hyperlipidemia and other risk factors for diet-
related chronic disease, intensive behavioral dietary counselling interventions 
are effective in changing average daily intake of core components of a 
healthy diet (including reduced saturated fat, and increased fi  bre, fruit, and 
vegetables). Effective interventions combine nutrition education with 
behavioral counselling provided by a nutritionist, dietician, or specially 
trained primary care clinician (e.g., physician, nurse, or nurse practitioner).70 
Another area of interest and growing research is micronutrient 
defi  ciencies. It is clear that an inadequate intake of specifi  c micronutrients 
is associated with an increased risk of both CVD and cancer. The approaches 
taken to increase micronutrients in a population include increasing the 
intake of micronutrient-rich foods, food fortifi   cation, and the use of 
supplements. While a strong association between consumption of high 
levels of vitamin D, vitamin C, folic acid, and beta-carotene and a lower risk 
of CVD, stroke, and cancer has been observed in cohort studies, a similar 
relationship has not been demonstrated in randomized trials of micronutrient 
supplements.97,98 It is not clear if the differences in clinical outcomes are 
due to the complex nature of micronutrients in whole foods (e.g., fruits and 
vegetables) versus the administration of a single micronutrient as a 
supplement or in fortifi  ed food. The research to date supports interventions 
that promote the consumption of whole foods or a dietary pattern (such as 
the Mediterranean diet) as the most effective approach for increasing 
micronutrient consumption, but fortifi   cation of basic foods with key 
micronutrients is also part of current best practices in public health. 
RECOMMENDED CLINICAL PREVENTIVE SERVICES FOR 
CHRONIC DISEASE PREVENTION
While the above review summarizes the policies and strategies that are 
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– tobacco use, physical inactivity and unhealthy diet – there are other 
intermediary endpoints such as high blood pressure and cholesterol, as well 
as additional screening tests, pharmaceuticals, and immunizations that are 
effective in the prevention and early detection of chronic disease and its 
precursors. 
We recognize that adoption of many of these recommendations may 
simply not be feasible in many LMICs due to limited resources and 
inadequate primary care and public health systems.2,99 Low-income 
populations generally have the least access to preventive care. Thus, a great 
deal of research is needed to fi  nd cost-effective ways to deliver clinical 
preventive services in LMICs. Dietary improvement to low-income 
populations, even in the industrialized societies with large gaps between 
upper and lower income groups, is an important element of current 
challenges to public health, including ready access to healthful foods such 
as fruit and vegetables of good quality and at reasonable prices.
Screening 
Screening involves the early detection of disease when the individual is 
asymptomatic. Screening is only recommended when there is evidence that 
early detection and treatment effectively reduce the risk of premature death 
and morbidity, and it is most effective when structural and economic 
barriers are reduced, when patients are reminded to come in for a screening 
procedure, and when they have access to education.69,70,100 Screening for 
tobacco use, physical activity and obesity were addressed in the previous 
sections of the paper.
Cancer screening: There is strong evidence to recommend cancer 
screening for breast, cervical, and colorectal cancer.70,100 However, the 
frequency and age range of recommendations vary by country and 
organization (Table 1), indicating that additional research is needed to 
determine the most cost-effective approach for improving health outcomes. 
Screening for other cancers, such as prostate cancer, has not proven to 
increase survival rates or quality of life for patients thus far.70140  Public Health Reviews, Vol. 32, No 1
Table 1
Cancer Screening Recommendations
by the United States and European Union
Organization Cervical Cancer Breast Cancer Colorectal cancer
U.S. Preventive 
Services Task 
Force70
Begin Pap 
screening within 
3 years of onset of 
sexual activity or 
age 21 (whichever 
comes fi  rst) and 
screen at least every 
3 years to age 65
Screening 
mammography every 
2 years for women 
aged 50 and older
Screening for colorectal 
cancer in adults ages 50 
to 74 years using one of 
three regimen: 1) annual 
fecal occult blood test 
(FOBT), 2) 
sigmoidoscopy every 
5 years combined with 
FOB every 3 years, or 3) 
screening colonoscopy 
at intervals of 10 years
European Code 
Against 
Cancer100
Pap screening every 
3-5 years for 
women ages 25-60
Mammography 
screening for women 
50-69 (interval not 
specifi  ed)
FOBT screening every 
two years for adults over 
50 
CVD Screening: Below we identify the individual screening tests for 
conditions that are precursors in developing CVD. However, it should be 
noted that the extent of the treatment for each of these risk factors should be 
adjusted to the absolute cardiovascular risk of each patient, as measured by 
the Framingham or SCORE equations, or country specifi  c equations (e.g., 
QRISK in England).101 There is strong evidence to support screening for:
Elevated Blood Pressure in adults aged 18 years and older. Adults with 
blood pressure below 120/80 mm Hg should be screened every two years, 
and those with systolic blood pressure of 120-139 mm Hg or diastolic 
blood pressure of 80 to 90 mm Hg, every year.70 Management and family 
education are for lifelong control of blood pressure by non-pharmaceutical 
means (e.g., smoking cessation, exercise) and use of low cost diuretics and 
beta blokers.
Lipid disorders in men aged 35 and older and men aged 20-35 if they 
are at increased risk for CVD; and in women aged 20 and older if they are 
at increased risk for CVD. The indicators for which there is strong evidence 
showing the value of screening include total serum cholesterol, low-density 
lipoprotein cholesterol (LDL-C), triglycerides (TG), or low values of high-
density lipoprotein cholesterol (HDL-C) on non-fasting or fasting blood Chronic Disease in the New Public Health  141
samples.70 Here too, management is a lifelong process with patient and 
family education as to self care and medical management.
Type 2 Diabetes Mellitus Screening in asymptomatic adults with 
sustained blood pressure (either treated or untreated) greater than 
135/80  mm Hg is recommended.70 Managing diabetes and preventing 
diabetes-related complications requires strict control of blood-glucose 
levels through diet, exercise, insulin replacement for type 1 diabetes, and 
insulin stimulation by medication for type 2 diabetes. This is best delivered 
with a multidisciplinary team approach and well organized follow-up.
CHEMOPROPHYLAXIS 
The pharmaceutical therapies that are effective in preventing heart disease, 
stroke, and cancer in asymptomatic patients are reviewed below.
Blood Pressure Medication: For persons with high blood pressure 
(over 140/90 mm Hg), the following drugs are effective in lowering blood 
pressure: in the US, a thiazide-type diuretic is recommended as the fi  rst 
course of treatment, and if needed, followed by an angiotensin converting 
enzyme inhibitor (ACE-I), an angiotensin receptor blocker (ARB), a beta 
blocker (BB), a calcium channel blocker (CBC), or a combination of the 
above.102 Under European guidelines, any of these fi   ve types of anti-
hypertensives are recommended as fi  rst line therapies.103
Hyperlipidemia Medication: For persons with elevated blood cholesterol 
and elevated low-density lipoproteins (LDL >130 mg/dL), the following 
drugs are effective in lowering LDL: statins, bile acid sequestrants, or 
nicotinic acid.104
Aspirin Therapy: The use of daily aspirin therapy for men aged 45-79 
and for women aged 55-79 is recommended when the potential benefi  t due 
to a reduction in myocardial infarction outweighs the potential harm due to 
increased gastrointestinal bleeding.70 This is most certainly the case for 
those with elevated risk factors and previous cardiovascular disease fi  ndings 
or events.
Chemoprevention of Breast Cancer: The U.S. Preventive Services 
Task Force (USPSTF) recommends against routine use of tamoxifen or 
raloxifene for the primary prevention of breast cancer in women at low or 
average risk.70 However, there is evidence that tamoxifen can reduce the 
risk for invasive estrogen-receptor-positive breast cancer in women at high 
risk and that the likelihood of benefi  t increases as the risk for breast cancer 
increases. There is less evidence for the benefi   t of raloxifene. It is 
recommended that clinicians discuss chemoprevention with women at high 
risk for breast cancer and at low risk for adverse effects of chemoprevention. 142  Public Health Reviews, Vol. 32, No 1
Imm  unizations and Control of Infectious Agents
Increasingly infectious agents in the form of bacteria and viruses are 
associated with the development of chronic disease. Below we review the 
evidence where an infectious agent has been identifi  ed and an immunization 
effective in preventing the chronic condition is available, or early medical 
management of the infection to prevent the development of the chronic 
condition has been developed.
Human papillomavirus: There is strong evidence to support vaccination 
of girls against HPV, which causes cervical cancer. The initial dose of the 
HPV vaccine should be administered to girls at age 11 or 12, followed by a 
second dose after two months and a third four months later. The HPV 
vaccine series should also be administered to females 13 to 26 years of age, 
if they have not been previously vaccinated.105 Pap smear screening of 
women should continue to be a fundamental part of preventive healthcare 
and supported by health insurance agencies and health education programs 
including outreach to low compliance risk groups.
Hepatitis B: To prevent chronic liver disease, it is recommended that all 
children be vaccinated against hepatitis B, the key determinant of chronic 
hepatitis, cirrhosis, and liver cancer. Children ages 7 and older should 
receive the hepatitis B and possibly hepatitis A vaccines. A three-dose 
series is recommended for children who have not previously been 
vaccinated. A two-dose series, separated by at least 4 months, of the adult 
formulation Recombivax HB (Reg), is recommended for children ages 11 
to 15.106
Helicobacter pylori: Finally, while there is presently no vaccine to 
prevent the contraction of Helicobacter pylori (HP), effective drug therapies 
that eliminate this infection in individuals are available. Timely treatment 
can prevent the development of chronic ulcers, gastric cancer, and a number 
of other pathologies associated with this virus.
GLOBAL RESPONSE TO CHRONIC DISEASE 
Progress in chronic disease prevention is uneven. Industrialized nations 
have achieved admirable improvements in overall health indicators (often 
as a result of advocacy groups and strong governmental action involving 
the community and professional support), although more attention should 
be paid to extending those results throughout the entire population. In 
contrast, developing countries with rapidly growing economies often have 
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while also adapting their health systems to care for their growing middle 
class, whose health profi  les are being quickly transformed. 
International agencies such as WHO and international NGOs are 
contributing to maintaining or expanding the focus on key chronic diseases 
globally, most recently through the Non-Communicable Diseases (NCD) 
Action Plan,107 as well as Regional Plans. These are a further refl  ection of 
the New Public Health approach, as multi-level and intersectoral actions 
are adapted to the national and regional context with an emphasis on 
surveillance and research. The National Heart, Lung, and Blood Institute 
(NHLBI) in the US has also made promising advances, establishing a 
consortium of Centers of Excellence in chronic disease management 
throughout LMICs. This work is being pursued in conjunction with local 
academic partners and authorities to foster research, training, and health 
policy at local, regional, national, and international levels.108
In LMICs, these challenges are hindered by lack of funding, shortages 
in qualifi   ed professionals and modern equipment, and problems with 
management and stewardship. All of these setbacks are framed within 
diffi  cult political and social contexts. 
PERSISTENT CHALLENGES IN CHRONIC DISEASE CONTROL 
IN THE INDUSTRIALIZED WORLD
In the past decades, research from developed countries has revealed many 
of the contributing and direct causes of the most deadly chronic diseases, as 
well as established evidence-based interventions that can have a very 
marked effect on these conditions and their associated mortality. We can 
point to important successes in CVD and cancer mortality, as well as in 
tackling tobacco use and physical inactivity. 
However, despite existing knowledge and skills with effective preventive 
measures, they are not adopted rapidly or even widely. They are not 
implemented homogeneously, even in countries that have made health and 
social equity a political priority. For example, many European countries 
have used strong welfare policies to narrow the income gap between the 
wealthiest and poorest citizens and to extend access to healthcare across 
society, yet lung cancer incidence and mortality is still closely related to 
socioeconomic status.109 
Thus, the most advanced health systems in the world still face an 
enormous challenge in living up to the noble goal of “universal” healthcare. 
Some of the blame can be attributed to shortcomings in health systems, 
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However, research is accumulating on other factors that may contribute to 
health inequalities as well, including poor health literacy,110 geographic 
factors (i.e., rural/urban inequalities or socioeconomic regional differences), 
and other key social determinants of health.111 
These newly explored complexities have contributed to the development 
of a New Public Health approach to address persistent challenges 
comprehensively in population health at the clinical, community, and 
societal levels. Governmental leadership with strong social advocacy group 
support is vital to the implementation of a New Public Health approach.
CHRONIC DISEASE CONTROL IN DEVELOPING COUNTRIES 
Unlike in Western countries, where wealthier and more highly educated 
people use tobacco less, eat healthier diets and lead more active lifestyles, 
the opposite appears to be true in emerging economies. As the benefi  ts of 
economic growth reach a population, consumption and health behaviors 
change quickly, with a tendency towards the adoption of unhealthy habits. 
Increased access to tobacco and unhealthful foods accompany societal 
shifts such as rapid urbanization, encouraging “modern” lifestyles, and 
technological progress leading to decreased physical activity have 
contributed to the spread of unhealthy behaviors. In rapidly developing 
countries such as India and China, this is especially apparent; as the 
economy grows, incidence of chronic disease increases as well.31
While public health activities focusing on chronic diseases have proven 
to be cost-effective, infectious diseases (in Africa, particularly HIV/AIDS) 
continue to dominate the attention of international donors and national 
health systems, overshadowing more silent killers such as CVD and cancer. 
Signifi  cantly, the portion of the WHO 2006-07 budget devoted to non-
communicable diseases accounted for just 12 percent of the total; 86 percent 
of WHO funds in the Western Pacifi  c region went towards combating 
infectious diseases, despite the fact that these pathologies are only 
responsible for 14 percent of the mortality burden.112 Notable advances have 
been made in many regions, most especially in tobacco control, but few 
developing countries have made heart disease, cancer or diabetes a priority. 
CONCLUSIONS AND RECOMMENDATIONS
Given the health burden that chronic disease represents in both developed 
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resulting from increased premature morbidity and mortality and rising 
healthcare costs, it is imperative that societies work together at all levels to 
address this issue. This begins at the policy level; evidence-based health 
policy should be an underlying thread in urban planning, education, 
agricultural policy, and health systems development, along with health 
targets to focus and proritize needed interventions at national, regional and 
local levels. Population-based preventive strategies are remarkably cost-
effective because increasing population health is also a way to ensure 
continuing capacity to produce wealth.113 This message should be highlighted 
in prevention advocacy at both a national and international level, particularly 
in emerging countries. Indeed, chronic conditions merit high priority in any 
sensible “Global New Public Health” agenda (defi  ned as the collective 
action we take worldwide for improving health and health equity).1
Numerous health organizations, universities, research groups, NGOs, 
donor groups, and development agencies, operating at national and 
international levels, play an important role in reducing chronic disease. Yet, 
too often these missions are hampered by poor coordination with the 
national health system and other actors, leading to overlap and gaps in 
research and population services. This is true not only in lower-income 
settings, but also in wealthier societies. For example, the EUROCAN+PLUS 
research project found that fragmented European cancer research “severely 
limits the total intellectual concentration on the wide cancer problem.”114 
National leadership is required to place health concerns high on national 
agendas. International organizations should help to promote national 
capacity building to meet such objectives.
In contrast, the Sector Wide Approach (SWAp) has been gaining favor 
worldwide. This strategy transfers the ownership of all health projects to 
the national health authorities to strengthen national autonomy. At the same 
time, different foreign and national organizations across the health sector 
forge a common and united mission through workshops and close 
networking.115 This approach makes sense on many levels; however, 
because each disease, country, and mission is different, release of evidence-
based recommendations can be diffi  cult. Future research must address the 
range of experiences that SWAp will produce. 
Communities also play an important role, and encouraging precedents 
exist that pave the way for further local action. For example, individual 
communities began instituting smoking bans in public places throughout 
the second part of the 20th century, and today these bans help protect the air 
quality and save lives in dozens of countries throughout the world. 
Additionally, community health networks established throughout rural 146  Public Health Reviews, Vol. 32, No 1
Kyrgyzstan to tackle specifi   c health problems at a community level 
produced improved health results.116
Finally, professionals and professional organizations throughout the 
health system must do their part to tackle population risk factors decisively 
and proactively according to evidence-based practice and clinical guidelines. 
This includes extending and advancing training in the fi  eld of chronic disease 
prevention, as well as making this a top research priority. As communities 
and national policy makers strive to improve population health outcomes, 
public health professionals and advocacy groups must learn to act as 
committed partners, guiding program development, advising the public, and 
working to validate or discard initiatives based on the outcomes observed. 
Ultimately, the New Public Health requires wide recognition as both an 
individual and public concern; more than a goal, it must become a collective 
value, sustaining our society’s quest for a better life for all human beings.117
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